Hyundai Bioscience Co., Ltd. (048410.KQ)
KRW 13990.0
(-1.82%)
KRW 13990.0
(-1.82%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 9.48 Billion KRW | 20.76% |
| 2022 | 7.85 Billion KRW | -15.04% |
| 2021 | 9.24 Billion KRW | -26.14% |
| 2020 | 12.51 Billion KRW | -58.41% |
| 2019 | 30.08 Billion KRW | -3.68% |
| 2018 | 31.23 Billion KRW | -2.3% |
| 2017 | 31.97 Billion KRW | -11.44% |
| 2016 | 36.1 Billion KRW | -11.24% |
| 2015 | 40.67 Billion KRW | 40.68% |
| 2014 | 28.91 Billion KRW | 13.21% |
| 2013 | 25.53 Billion KRW | -31.13% |
| 2012 | 37.07 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 5.04 Billion KRW | 345.42% |
| 2024 Q2 | 1.09 Billion KRW | -78.35% |
| 2023 Q3 | 1.96 Billion KRW | -39.08% |
| 2023 Q1 | 3.16 Billion KRW | 84.58% |
| 2023 FY | 9.48 Billion KRW | 20.76% |
| 2023 Q4 | 1.13 Billion KRW | -42.25% |
| 2023 Q2 | 3.22 Billion KRW | 1.89% |
| 2022 FY | 7.85 Billion KRW | -15.04% |
| 2022 Q4 | 1.71 Billion KRW | -28.1% |
| 2022 Q1 | 2.34 Billion KRW | -7.05% |
| 2022 Q2 | 1.41 Billion KRW | -39.7% |
| 2022 Q3 | 2.38 Billion KRW | 68.69% |
| 2021 Q1 | 1.95 Billion KRW | -1.14% |
| 2021 Q4 | 2.52 Billion KRW | 2.33% |
| 2021 FY | 9.24 Billion KRW | -26.14% |
| 2021 Q2 | 2.3 Billion KRW | 18.03% |
| 2021 Q3 | 2.46 Billion KRW | 6.85% |
| 2020 Q1 | 4.17 Billion KRW | -46.0% |
| 2020 Q3 | 2.96 Billion KRW | -12.86% |
| 2020 Q4 | 1.97 Billion KRW | -33.27% |
| 2020 FY | 12.51 Billion KRW | -58.41% |
| 2020 Q2 | 3.39 Billion KRW | -18.72% |
| 2019 Q4 | 7.73 Billion KRW | 18.1% |
| 2019 Q3 | 6.55 Billion KRW | -17.71% |
| 2019 Q2 | 7.96 Billion KRW | 1.68% |
| 2019 Q1 | 7.83 Billion KRW | -14.26% |
| 2019 FY | 30.08 Billion KRW | -3.68% |
| 2018 FY | 31.23 Billion KRW | -2.3% |
| 2018 Q3 | 7.43 Billion KRW | -12.8% |
| 2018 Q2 | 8.52 Billion KRW | 38.82% |
| 2018 Q1 | 6.14 Billion KRW | -46.44% |
| 2018 Q4 | 9.13 Billion KRW | 22.86% |
| 2017 Q3 | 7.99 Billion KRW | 21.78% |
| 2017 FY | 31.97 Billion KRW | -11.44% |
| 2017 Q2 | 6.56 Billion KRW | 10.33% |
| 2017 Q1 | 5.94 Billion KRW | -45.41% |
| 2017 Q4 | 11.46 Billion KRW | 43.49% |
| 2016 Q3 | 8.38 Billion KRW | 18.27% |
| 2016 Q4 | 10.89 Billion KRW | 29.96% |
| 2016 FY | 36.1 Billion KRW | -11.24% |
| 2016 Q1 | 9.73 Billion KRW | 17.39% |
| 2016 Q2 | 7.08 Billion KRW | -27.17% |
| 2015 Q3 | 7.51 Billion KRW | -42.53% |
| 2015 Q1 | 11.78 Billion KRW | 35.72% |
| 2015 FY | 40.67 Billion KRW | 40.68% |
| 2015 Q4 | 8.29 Billion KRW | 10.31% |
| 2015 Q2 | 13.08 Billion KRW | 10.98% |
| 2014 Q3 | 7.05 Billion KRW | 24.87% |
| 2014 Q1 | 7.51 Billion KRW | 10.07% |
| 2014 FY | 28.91 Billion KRW | 13.21% |
| 2014 Q4 | 8.68 Billion KRW | 23.03% |
| 2014 Q2 | 5.65 Billion KRW | -24.8% |
| 2013 Q2 | 5.18 Billion KRW | -37.57% |
| 2013 Q4 | 6.82 Billion KRW | 30.85% |
| 2013 Q3 | 5.21 Billion KRW | 0.66% |
| 2013 FY | 25.53 Billion KRW | -31.13% |
| 2013 Q1 | 8.3 Billion KRW | -29.23% |
| 2012 Q4 | 11.73 Billion KRW | 0.0% |
| 2012 FY | 37.07 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Sam Chun Dang Pharm. Co., Ltd | 192.66 Billion KRW | 95.079% |
| ST Pharm Co.,Ltd. | 284.99 Billion KRW | 96.673% |
| ABL Bio Inc. | 65.54 Billion KRW | 85.535% |
| Cellid, Co., Ltd. | - KRW | -Infinity% |